MLchartDataset catalogue

Krazati

Term · Oncology and biomedicine · MLC-T-ONC-004666

A drug used alone or with cetuximab to treat adults with colorectal cancer or non-small cell lung cancer that has spread and has a certain mutation (change) in the KRAS gene. It is used in patients whose cancer was treated with other systemic therapy. It is also being studied in the treatment of other types of cancer. Krazati blocks a protein (KRAS G12C) made by the mutated KRAS gene, which may help keep cancer cells from growing and may kill them. It is a type of targeted therapy. Also called adagrasib.

Table 1. Record
IdentifierMLC-T-ONC-004666
FieldOncology and biomedicine
Synonymsadagrasib
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-004666",
  "term": "Krazati",
  "field": "Oncology and biomedicine",
  "definition": "A drug used alone or with cetuximab to treat adults with colorectal cancer or non-small cell lung cancer that has spread and has a certain mutation (change) in the KRAS gene. It is used in patients whose cancer was treated with other systemic therapy. It is also being studied in the treatment of other types of cancer. Krazati blocks a protein (KRAS G12C) made by the mutated KRAS gene, which may help keep cancer cells from growing and may kill them. It is a type of targeted therapy. Also called adagrasib.",
  "synonyms": [
    "adagrasib"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/krazati/"
}

Record 9,836 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.